Tag: "hodgkin" at biology news

FLT PET assesses treatment response on tumor growthnot sizewith non-Hodgkin's lymphoma

SAN DIEGO, Calif.--Positron emission tomography (PET)--with the radiolabeled thymidine analog [18F]Fluorothymidine (FLT)--is "a promising, sensitive tool" for assessing drug effects on tumor growth in patients with diffuse large B-cell lymphoma, according to a study released at SNM's 53rd Annual Meeting June 37 in San Diego.... ... "Conventional imaging modalities--such as computed tomography, ul...

BiovaxID yields 89 percent survival in patients with aggressive non-Hodgkins

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) and its subsidiary, Biovest International, Inc. (OTCBB:BVTI), report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients. The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50...

PCBs, furans may factor in risk of non-Hodgkin lymphoma

Scientists have found some additional evidence that environmental exposure to polychlorinated biphenyls (PCBs) may be associated with non-Hodgkin lymphoma, according to a study published in the December 1 issue of Cancer Research....... By comparing blood levels of PCBs in 100 pairs of healthy volunteers and non-Hodgkin lymphoma patients, Anneclaire De Roos, Ph.D., assistant professor of epidemio...

Positive effects of nuclear medicine, 'smart drugs' provide hope for non-hodgkin's lymphoma patients

TORONTO, Canada--Three scientific studies--each highlighting new discoveries in treatment for patients with non-Hodgkin's lymphoma--were announced at the Society of Nuclear Medicine's 52nd Annual Meeting June 1822 in Toronto. ...... "Nuclear medicine has a growing role in treating non-Hodgkin's lymphoma," said SNM member Richard L. Wahl, M.D., director of nuclear medicine/PET at the Russell H. Mo...

Hepatitis C virus linked to non-Hodgkin's lymphoma

SEATTLE--Patients infected with the hepatitis C virus (HCV) are six times as likely to develop non-Hodgkin's lymphoma (NHL) than individuals that are virus free, according to research presented today at the Third Annual Frontiers in Cancer Prevention Research meeting.... HCV infected patients have a seventeen fold higher risk for developing diffuse large B-Cell lymphoma, researchers from British...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
Other Tags
funnelnonexponentialapo2lunfoundedthoughtspearlsyieldingdesinfectantiviralsoutdatedbahrainquartersthreefacesidentity